Xolair 300 MG/2 ML syringe 2ML
Ended Awarded
- Contract number
- SPE2DB26FXRC2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,581
Award facts
- Contract value 100% obligated
- $5,581.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,581.44 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. This firm fixed-price delivery order, issued on October 16, 2025, with an ultimate completion date of November 6, 2025, was not subject to any set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA—the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V)—a $30.3 billion acquisition strategy establishing multiple regional prime vendor contractors to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and established track record to fulfill diverse and specialized medical requirements for military healthcare operations. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with demonstrated performance across numerous delivery orders issued by the DLA's Medical Supply Chain division. The PPV-G GEN V contract, awarded November 13, 2025, features a $499.999 billion ceiling value and extends through December 31, 2036, with a 30-month base period followed by three optional 30-month renewal periods, positioning DMS Pharmaceutical Group to serve as a sustained pharmaceutical supplier for Department of Defense operations globally.
Quick answers
Who was awarded contract SPE2DB26FXRC2?
SPE2DB26FXRC2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 16, 2025.
How much is contract SPE2DB26FXRC2 worth?
The government has obligated $5,581 on SPE2DB26FXRC2.
Is contract SPE2DB26FXRC2 an order under another contract?
Yes. SPE2DB26FXRC2 is a delivery order under SPE2DB24D9131, an indefinite delivery contract.
Was contract SPE2DB26FXRC2 competed?
The extent of competition for SPE2DB26FXRC2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award